
DEFINE-HT Study Shows Prospera™ Heart Predicts Outcomes Better Than Biopsy
DEFINE-HT Clinical Trial Shows Prospera™ Heart Accurately Predicts Outcomes and Outperforms Biopsy in Heart Transplant Surveillance Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing,…












